Patents Assigned to the Secretary, Department of
-
Patent number: 11976109Abstract: Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.Type: GrantFiled: December 31, 2018Date of Patent: May 7, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nancy Sullivan, Kendra Leigh, John Misasi, Alberto Cagigi
-
Patent number: 11976299Abstract: Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.Type: GrantFiled: September 18, 2017Date of Patent: May 7, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gal Cafri, Paul F. Robbins, Jared J. Gartner, Steven A. Rosenberg
-
Patent number: 11975063Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.Type: GrantFiled: February 1, 2022Date of Patent: May 7, 2024Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter L. Collins, Ursula J. Buchholz, Bo Liang, Shirin Munir
-
Publication number: 20240140909Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary system are disclosed. Certain heptamethine cyanines exhibit biliary system specificity and methods for in vivo visualization of a biliary system of a subject are provided. The methods may be for diagnostic purposes and/or for visualization of biliary systems during surgery.Type: ApplicationFiled: November 27, 2023Publication date: May 2, 2024Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Martin John Schnermann, Roger Rauhauser Nani
-
Publication number: 20240139112Abstract: In an embodiment, the invention provides an isolated population of exosomes comprising interleukin-27 (IL-27) or interleukin-35 (IL-35). In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-27 (IL-27), the method comprising: (a) isolating CD19+B2 cells or B1a cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-35 (IL-35), the method comprising: (a) isolating CD138+plasma cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. Additional embodiments of the invention are as described.Type: ApplicationFiled: May 28, 2021Publication date: May 2, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Charles E. Egwuagu, Minkyung Kang
-
Patent number: 11970528Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: February 3, 2020Date of Patent: April 30, 2024Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 11969466Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 8, 2023Date of Patent: April 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Publication number: 20240132619Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: ApplicationFiled: September 19, 2023Publication date: April 25, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Patent number: 11964010Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: GrantFiled: March 8, 2021Date of Patent: April 23, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Publication number: 20240124935Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.Type: ApplicationFiled: December 27, 2023Publication date: April 18, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
-
Patent number: 11959096Abstract: Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.Type: GrantFiled: September 18, 2020Date of Patent: April 16, 2024Assignees: The Medical College of Wisconsin, Inc., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services NIH, Office of Technology TransferInventors: Rebekah L. Gundry, Kenneth R. Boheler, Erin M. Kropp
-
Publication number: 20240117011Abstract: Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies.Type: ApplicationFiled: February 4, 2022Publication date: April 11, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: John Misasi, Lingshu Wang, Chaim Aryeh Schramm, John R. Mascola, Daniel Cesar Douek, Nancy J. Sullivan, Amy Ransier Henry, Tongqing Zhou, Peter D. Kwong, Wei Shi, Yi Zhang, Eun Sung Yang, Mario Roederer, Rosemarie Diana Mason, Amarendra Pegu, Julie E. Ledgerwood
-
Publication number: 20240117026Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: August 2, 2023Publication date: April 11, 2024Applicants: The U.S.A., as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20240115261Abstract: A surgical clamp for aligning the margins of incised or wounded tissue has jaws with parallel clamping faces, and a handle for manipulating the clamp to align the margins of the tissue. The jaws are in a normally closed position, however they can be opened by compressing the handle to open the jaws. Prongs project from the inferior surface of the jaws. The clamp is positioned in a desired position over the margins of a wound to be closed, the prongs engage the margins of the wound to be aligned, and the jaws are closed by releasing compressive force on the handle. As the jaws close the prongs help move the tissue into alignment. Suture guide slots through the jaws assist in the placement of precisely placed sutures across the incision. The disclosed surgical clamp is particularly suited for selectively closing and reopening surgical incisions, such as a sclerotomy incision in the eye. Methods are disclosed for using the clamp during intraocular and other surgical or minimally invasive procedures.Type: ApplicationFiled: July 25, 2023Publication date: April 11, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Vladimir R. Khristov, Steven T. Charles, Juan A. Amaral, Arvydas Maminishkis, Kapil Bharti
-
Patent number: 11951217Abstract: Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.Type: GrantFiled: May 20, 2022Date of Patent: April 9, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of StrathelydeInventors: Chintamani Atreya, Michelle Maclean, John G. Anderson, Scott J. MacGregor
-
Patent number: 11951131Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: GrantFiled: June 26, 2019Date of Patent: April 9, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: James N. Kochenderfer, Steven A. Feldman
-
Publication number: 20240101685Abstract: Provided herein are methods of treating a subject with cancer using a therapeutically effective amount of one or more one or more tumor-specific antibody-IR700 molecules. The methods can further include administering to the subject a therapeutically effective amount of (a) one or more CTLA4 antibody-IR700 molecules, one or more PD-L1 antibody-IR700 molecules, or combinations thereof, (b) one or more reducing agents, (c) one or more immunoactivators, or combinations of a, b, and c, for example, either simultaneously or substantially simultaneously with the tumor-specific antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The method also includes irradiating the subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2. The use of one or more reducing agents can reduce edema resulting from treatment.Type: ApplicationFiled: January 28, 2022Publication date: March 28, 2024Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20240101609Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: December 12, 2023Publication date: March 28, 2024Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servi, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Patent number: 11939297Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.Type: GrantFiled: February 10, 2023Date of Patent: March 26, 2024Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
-
Patent number: 11939377Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.Type: GrantFiled: July 11, 2019Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry